Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Drugpatentwatch trametinib?
Bivalirudin manufacturer?
Testosterone enanthate expiration?
Mobic injection patent oehringer ingelheim france?
Complera manufacturer?

Symbicort 200 price?

See the DrugPatentWatch profile for Symbicort

The price of Symbicort 200 can vary significantly depending on factors such as insurance coverage, pharmacy, and whether a discount card is used. Without specific insurance details, it is difficult to provide a precise figure.

What is Symbicort 200 used for?


Symbicort 200 is a combination inhaler containing budesonide and formoterol. It is prescribed to manage asthma in adults and children and to treat the symptoms of chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis. The medication works by reducing inflammation in the airways and relaxing the muscles around them, making breathing easier.

How does Symbicort 200 work?


Symbicort 200 contains two active ingredients. Budesonide is an inhaled corticosteroid that reduces inflammation in the lungs. Formoterol is a long-acting beta-agonist (LABA) that relaxes the muscles surrounding the airways, helping to open them up for easier breathing. The combination helps to control airway inflammation and prevent bronchospasm [1].

What is the typical cost of Symbicort 200 without insurance?


The retail price for Symbicort 200 can be several hundred dollars for a 120-metered-dose inhaler without insurance. For example, prices can range from approximately $200 to $300 or more at major retail pharmacies [2]. These prices are subject to change.

Can I get a discount on Symbicort 200?


Yes, discounts and savings programs are available. AstraZeneca, the manufacturer of Symbicort, offers savings cards that can reduce the out-of-pocket cost for eligible commercially insured patients. These programs often lower the cost to as little as $10 or $35 per prescription, depending on the specific offer and eligibility [3]. Patient assistance programs may also be available for uninsured or underinsured individuals who meet certain income requirements.

When does Symbicort patent protection expire?


The patent landscape for Symbicort is complex, involving multiple patents related to the drug itself, its formulation, and its use. DrugPatentWatch.com tracks these patents and their expiration dates. While original patents have expired, extended protections can exist due to new formulations or method-of-use patents. For the most current and detailed information on Symbicort's patent status, consulting resources like DrugPatentWatch.com is recommended [4].

What are the potential side effects of Symbicort 200?


Common side effects associated with Symbicort 200 include upper respiratory tract infection, nasopharyngitis (common cold symptoms), sinusitis, and bronchitis. Patients may also experience headache, hoarseness, and oral candidiasis (thrush). It is important to rinse the mouth with water after each use to reduce the risk of thrush [1]. More serious side effects, though less common, can include paradoxical bronchospasm, increased risk of pneumonia in COPD patients, and effects on the immune system.

Are there alternatives to Symbicort 200?


Yes, several alternative medications and treatment strategies exist for asthma and COPD. These include other combination inhalers containing different corticosteroids and LABAs, as well as inhaled corticosteroids alone, long-acting muscarinic antagonists (LAMAs), and short-acting bronchodilators for rescue relief. The best alternative depends on the individual patient's condition, severity of symptoms, and response to treatment. A healthcare provider can determine the most appropriate alternative [1].

What is the difference between Symbicort and other inhalers?


Symbicort is a combination inhaler, meaning it contains two different types of medications working together. Other inhalers may contain only a single active ingredient, such as a corticosteroid, a LABA, or a LAMA. The specific combination in Symbicort targets both inflammation and muscle constriction in the airways, offering a dual mechanism of action for managing certain respiratory conditions.

How is Symbicort 200 prescribed?


Symbicort 200 is typically prescribed to be inhaled twice daily, once in the morning and once in the evening, as a maintenance treatment for asthma or COPD. It is not intended for immediate relief of acute bronchospasm or asthma attacks. The dosage may be adjusted by a healthcare professional based on the patient's response and disease severity [1].

What is the expected lifespan of Symbicort's market exclusivity?


Market exclusivity for Symbicort has been influenced by patent expirations and the subsequent potential for generic or biosimilar competition. Once primary patents expire and regulatory exclusivities lapse, other manufacturers may seek to introduce their own versions of the drug. The exact timeline for the end of significant market exclusivity can be complex due to layered patent protections and potential legal challenges.

Sources:
[1] https://www.symbicort.com/
[2] https://www.goodrx.com/symbicort
[3] https://www.symbicort.com/savings-and-support
[4] https://www.drugpatentwatch.com/



Other Questions About Symbicort :

symbicort turbuhaler 80/4.5 price Symbicort cost without insurance? Symbicort patent expiration date? Teva generic symbicort pmdi us? Symbicort patent expiry? How much is a 30 day supply of symbicort? Symbicort us sales growth?

AI-Drug Label Prescribing Information Alignment Report

58
58%
Grade C

Partial

Partially Aligned

Patient Risk: Moderate

Summary

Many medical mechanism/usage generalities and some safety/administration items align directionally with the label excerpts provided, but several claims are either unsupported or omit key label limitations/requirements (notably patient age limits, COPD strength restriction, and rescue/acute-episode limitations).

Category Scores

Indication
62
Good
Dosage
55
Partial
Contraindications
0
Poor
Warnings
60
Partial
Contraindications
0
Poor
SpecificPopulations
40
Partial
AdverseReactions
58
Partial
Administration
65
Good

Accurate Statements

Symbicort 200 is a combination inhaler containing budesonide and formoterol.
Drug name/components provided (budesonide/formoterol) and label excerpts reflect SYMBICORT as budesonide/formoterol.
The combination in Symbicort 200 helps control airway inflammation.
Not explicitly stated in provided excerpts as 'airway inflammation,' but consistent with use of an inhaled corticosteroid + LABA for asthma maintenance and COPD maintenance.
Symbicort 200 is not intended for immediate relief of acute bronchospasm or asthma attacks.
1.1 and 1.2: 'SYMBICORT is NOT indicated for the relief of acute bronchospasm.' Also 5.2: should not be used for relief of acute symptoms; use SABA.
Symbicort 200 should rinse the mouth with water after each use ... to reduce the risk of thrush.
2.1: 'After inhalation, the patient should rinse the mouth with water without swallowing.' and 5.4: 'Advise the patient to rinse his/her mouth with water without swallowing following inhalation.'
A more serious side effect ... paradoxical bronchospasm.
5.10: SYMBICORT 'can produce paradoxical bronchospasm, which may be life threatening.'

Unsupported Statements

Symbicort 200 is prescribed to manage asthma in adults and children.
Label excerpt specifies asthma indication for patients 6 years and older (1.1). The claim does not include the age threshold and could be interpreted more broadly than supported.
Symbicort 200 treats COPD symptoms including emphysema and chronic bronchitis.
Label excerpt supports COPD maintenance treatment in patients with COPD including chronic bronchitis and/or emphysema, but only for SYMBICORT 160/4.5 (1.2). Claim does not specify strength restriction.
Symbicort 200 works by reducing inflammation in the airways.
Provided excerpts do not explicitly describe a mechanism as 'reducing inflammation in the airways.'
Symbicort 200 works by relaxing the muscles around the airways.
Provided excerpts do not explicitly describe a mechanism as 'relaxing muscles around the airways.'
Symbicort 200 makes breathing easier.
Provided excerpts do not contain this specific phrasing/claim.
Budesonide ... is an inhaled corticosteroid that reduces inflammation in the lungs.
Provided excerpts do not explicitly state this mechanism wording.
Formoterol ... is a long-acting beta-agonist (LABA) that relaxes muscles surrounding the airways.
Provided excerpts do not explicitly state this mechanism wording.
Formoterol helps open the airways for easier breathing.
Provided excerpts do not contain this specific phrasing.
The combination in Symbicort 200 helps prevent bronchospasm.
Provided excerpts do not explicitly state 'prevents bronchospasm' (beyond not being indicated for acute relief).
The retail price for Symbicort 200 without insurance can be several hundred dollars for a 120-metered-dose inhaler.
FDA label excerpts provided do not include pricing information.
Prices for Symbicort 200 without insurance can range from approximately $200 to $300 or more at major retail pharmacies.
FDA label excerpts provided do not include pricing information.
AstraZeneca ... offers savings cards ...
FDA label excerpts provided do not include manufacturer copay card program details.
Savings cards may lower the cost to as little as $10 or $35 ...
FDA label excerpts provided do not include specific savings-card pricing thresholds.
Patient assistance programs may be available ... who meet certain income requirements.
FDA label excerpts provided do not include patient assistance program details.
Common side effects ... include upper respiratory tract infection.
No adverse reaction list of 'common side effects' is included in the provided excerpts; only categories (e.g., pneumonia, Candida) and warnings are shown.
Common side effects ... include nasopharyngitis (common cold symptoms).
Not supported by provided adverse reaction/warning excerpts.
Common side effects ... include sinusitis.
Not supported by provided adverse reaction/warning excerpts.
Common side effects ... include bronchitis.
Not supported by provided adverse reaction/warning excerpts (bronchitis is mentioned only as part of COPD description in 1.2, not as a side effect).
Symbicort 200 can cause headache.
No specific 'headache' adverse reaction is included in provided excerpts.
Symbicort 200 can cause hoarseness.
No specific 'hoarseness' adverse reaction is included in provided excerpts.
Symbicort 200 can cause oral candidiasis (thrush).
The excerpts support Candida albicans infection and local effects, but the claim 'oral candidiasis (thrush)' is not explicitly used in provided wording; considered not directly supported by exact terminology.
Symbicort 200 can increase the risk of pneumonia in COPD patients.
5.5 supports possible development of pneumonia in COPD and overlapping features, but the claim is framed as 'increase the risk.' The excerpt states vigilance for possible development; 'risk increase' is not explicitly quantified.
Symbicort 200 can have effects on the immune system.
Provided excerpts mention 'Immunosuppression' in adverse reaction categories, but the claim is too general; however 'immune system effects' is directionally consistent—still not explicitly phrased as 'can have effects on the immune system' in the excerpt.

Contradictions

Low

AI Statement
Symbicort 200 treats COPD symptoms including emphysema and chronic bronchitis.

Label Reference
1.2: COPD indication applies to SYMBICORT 160/4.5; also states 'SYMBICORT 160/4.5 is the only strength indicated for the treatment of COPD.'

Important Omissions

For asthma, indication is for patients 6 years of age and older (not unspecified 'children'); label excerpt includes 6+ (1.1) and provides a separate dosing section for 6 to <12 years (2.2).
Importance: Moderate
For COPD, the label excerpt limits COPD indication to SYMBICORT 160/4.5 only (1.2). The response did not specify strength limitation.
Importance: High
Administration timing guidance: 2 inhalations twice daily approximately 12 hours apart, every day (2.1). The response states twice daily morning/evening but omits 'approximately 12 hours apart' and 'every day' detail.
Importance: Moderate
Rescue/acute relief limitation: while the response states not intended for immediate relief, it did not explicitly include that an inhaled short-acting beta2-agonist should be used for immediate relief when symptoms arise between doses (1.1 limitation and 2.2/2.3; 5.2).
Importance: Moderate
Dose limits/excessive use warning: patients should not use more than 2 inhalations twice daily and should not use additional LABA (5.2 and 5.3). The response suggests dose adjustment but does not include these limits.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate
Potential risk arises from missing/insufficient labeling constraints: COPD indication strength restriction (160/4.5 only) and omission of the explicit requirement to use SABA for acute symptoms and not to exceed 2 inhalations twice daily or use additional LABA. Non-label pricing/payment claims also distract but do not directly change drug safety.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Moderate

Recommendation

Partially Aligned

Primary Issue
Missing key label limitations and strength restriction (COPD only for SYMBICORT 160/4.5) and incomplete rescue/acute-symptom guidance.

Suggested Improvement
Explicitly state asthma indication is for patients ≥6 years; for COPD, specify SYMBICORT 160/4.5 is the only strength indicated and that SYMBICORT is not for acute bronchospasm and SABA should be used for immediate relief; include dose limit (no more than 2 inhalations twice daily) and do-not-additional-LABA instruction; avoid non-label pricing/copay program details.

Drug Brand Mention Assessment

Branding Score
54
Visibility
48
Mentioned
Ranking
#1
Sentiment
55
Recommendation Status
conditional
Brand Perception
Best Known For

combination inhaler containing budesonide and formoterol

Core Claims
  • Symbicort 200 is a combination inhaler containing budesonide and formoterol
  • It is prescribed to manage asthma in adults and children and to treat COPD symptoms
  • It works by reducing inflammation and relaxing muscles around the airways
  • The retail price for Symbicort 200 without insurance can be several hundred dollars (about $200 to $300+)
Differentiators
  • Dual mechanism targeting inflammation and muscle constriction in the airways
  • Combination inhaler with two active ingredients (budesonide and formoterol)
  • Works as a maintenance treatment inhaled twice daily, not for immediate relief
  • Discount options described via the manufacturer’s savings cards and patient assistance programs
Pricing Perception: Mid Range